Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194343 | 0.81 | MAPT (0.36) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824565 | 0.79 | MAPT (0.41) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824602 | 0.77 | MAPT (0.38) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824589 | 0.77 | MAPT (0.34) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824584 | 0.70 | MAPT (0.38) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL10194339 | 0.69 | RAB9A (0.43) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL10234014 | 0.69 | MAPT (0.38) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824849 | 0.68 | MAPT (0.60) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824567 | 0.68 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL824842 | 0.67 | MAPT (0.38) | MAPTRAB9ASMN1; SMN2NPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142519-B2 | Azo pigment, and pigment dispersion, coloring composition and ink composition for inkjet recording containing the same | FUJIFILM CORPORATION (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20100258036-A1 | AZO PIGMENT, AND PIGMENT DISPERSION, COLORING COMPOSITION AND INK COMPOSITION FOR INKJET RECORDING CONTAINING THE SAME | FUJIFILM CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100258036-A1 | AZO PIGMENT, AND PIGMENT DISPERSION, COLORING COMPOSITION AND INK COMPOSITION FOR INKJET RECORDING CONTAINING THE SAME | WNT1, CYP1A1, CYP1B1 | MAPT 372/4885RAB9A 910/4885SMN1; SMN2 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.